Cancer patients who have heart attacks are typically not treated with a course of life-saving aspirin because of the belief that these patients might experience lethal bleeding.

This belief is now under dispute and researchers at The University of Texas M. D. Anderson Cancer Center say that without aspirin, the majority of these patients will die. Their arguments, subject of a recent study, will be published in the February 1 issue of the journal Cancer.

Aspirin has been viewed as harmful because of its tendency to thin blood. Because cancer patients can experience low platelet counts and abnormal clotting, aspirin has been considered a contraindication. But this study found that nine of 10 cancer patients with low platelet counts who experienced heart attacks and who did not receive aspirin died. Only one patient died, however, in a group of 17 cancer patients who received aspirin.

This conclusion -- that aspirin helps people with cancer just as it does for people without cancer -- may help medical professionals determine guidelines for treatment of heart attacks in cancer patients. Because right now, physicians are uncertain about how to balance treatment for both conditions.